Summary: The Centers for Medicare & Medicaid Services modified its Hepatitis Panel/Acute Hepatitis Panel coverage policy, effective May 15, 2026. Here's what billing teams need to do.
CMS updated its coverage policy for hepatitis panel and acute hepatitis panel testing. The specific policy does not carry a numbered policy code in this version. The underlying policy data did not include specific CPT or ICD-10 codes — we've noted that below in the codes section. If your lab or clinic bills hepatitis panel testing to Medicare patients, this change affects your billing and your claim denial exposure starting May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Hepatitis Panel / Acute Hepatitis Panel |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium-High |
| Specialties Affected | Clinical laboratory, gastroenterology, infectious disease, internal medicine, urgent care, primary care |
| Key Action | Audit your hepatitis panel charge capture and documentation workflows before May 15, 2026 |
CMS Hepatitis Panel Coverage Criteria and Medical Necessity Requirements 2026
The CMS hepatitis panel coverage policy governs when Medicare will reimburse for hepatitis antibody and antigen testing ordered as a panel rather than individual components. Medical necessity is the central issue here — and it always has been with panel testing. CMS scrutinizes whether every component in a panel meets the medical necessity standard for that specific patient at that specific encounter.
For hepatitis panels, medical necessity typically requires clinical indication of acute or chronic hepatitis exposure, symptoms consistent with liver disease, or risk factors that justify broad panel ordering. Ordering a full acute hepatitis panel on a patient with no documented risk factors, no symptoms, and no clinical rationale is the fastest path to a claim denial. Your ordering providers need to understand that.
The acute hepatitis panel specifically evaluates for simultaneous infection across hepatitis A, B, and C. It's ordered when a provider can't clinically distinguish which hepatitis type is responsible for a patient's presentation. That distinction — acute versus chronic, and A versus B versus C — drives the medical necessity argument on every claim.
CMS medical necessity requirements for laboratory panels hinge on documented clinical context. The ordering physician's note must reflect why a panel — rather than targeted individual tests — was appropriate. "Rule out hepatitis" without more doesn't cut it. The note should document symptoms, relevant exposure history, or clinical findings that support broad testing.
Prior authorization is not typically required for hepatitis panel testing under Medicare fee-for-service. But prior authorization requirements can vary under Medicare Advantage plans, which operate under separate coverage rules. If your patient population includes significant Medicare Advantage volume, verify each plan's prior authorization rules separately.
CMS Hepatitis Panel Exclusions and Non-Covered Indications
Hepatitis panel testing ordered as a screening tool — without documented symptoms, known exposure, or clinical indication — falls outside Medicare's medical necessity standard. CMS does not cover routine screening through the hepatitis panel codes in the absence of clinical indication. That's a separate coverage category with its own rules and, in some cases, specific preventive service billing.
Duplicate testing is another exclusion trigger. If hepatitis markers were already established through prior testing and the clinical picture hasn't changed, re-ordering the full panel lacks medical necessity support. Your documentation should show why repeat testing was clinically warranted — not just that a provider checked the box again.
Testing ordered purely for administrative or insurance purposes without clinical indication also falls outside CMS coverage policy. The standard is clinical need, not administrative convenience.
Coverage Indications at a Glance
This table reflects standard CMS medical necessity standards for hepatitis panel testing. The source policy did not include specific indication-level criteria in its data. The rows below reflect established Medicare coverage principles for this test category.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Acute hepatitis presentation with undifferentiated etiology | Covered | Not listed in source policy | Clinical documentation of symptoms and exposure required |
| Known or suspected hepatitis A, B, or C exposure with symptoms | Covered | Not listed in source policy | Must document exposure history in the clinical note |
| Routine screening without clinical indication | Not Covered | Not listed in source policy | Preventive screening may have separate billing pathways |
| Repeat panel without new clinical indication | Not Covered | Not listed in source policy | Prior results and unchanged clinical status = denial risk |
| Administrative-only testing without clinical need | Not Covered | Not listed in source policy | CMS medical necessity standard requires clinical basis |
CMS Hepatitis Panel Billing Guidelines and Action Items 2026
The modified CMS coverage policy takes effect May 15, 2026. Here are your concrete steps before that date.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for hepatitis panel codes before May 15, 2026. Pull claims from the past 90 days. Flag any hepatitis panel claims where the ordering documentation doesn't clearly support medical necessity. If you're seeing patterns of thin documentation, that's your signal to intervene before the new policy version is active. |
| 2 | Train your ordering providers on documentation requirements now. The ordering note must reflect clinical indication — symptoms, exposure history, or lab findings — not just a panel checkbox. A brief documentation tip sheet circulated before May 15 can cut your downstream denial rate meaningfully. |
| 3 | Review your ABN workflow for hepatitis panel testing. If a patient's clinical situation puts medical necessity in question — for example, a provider wants a panel for a purpose that doesn't meet CMS criteria — issue an Advance Beneficiary Notice of Noncoverage before the test runs. Don't wait for the denial to arrive. |
| 4 | Separate your Medicare Advantage hepatitis panel billing guidelines from your Medicare fee-for-service workflow. Medicare Advantage plans follow their own coverage policy rules. Prior authorization requirements, coverage criteria, and reimbursement rates can differ substantially. Treating all Medicare as identical is one of the most common billing mistakes in lab settings. |
| 5 | Check with your Medicare Administrative Contractor (MAC) for local coverage determination (LCD) guidance. Some MACs have issued LCDs that are more specific than the national CMS position on hepatitis panel medical necessity. Your MAC's LCD — if one exists for your region — sets the floor for your documentation requirements. Don't rely solely on national policy when regional guidance is stricter. |
| 6 | If your billing team hasn't reviewed CMS hepatitis panel billing guidelines recently, do it now. This policy modification is your trigger. Assign someone to pull the current and previous policy versions, compare them side-by-side, and document what changed. That comparison drives your internal update checklist. |
| 7 | Loop in your compliance officer if you have significant Medicare hepatitis panel volume. If this test category represents meaningful reimbursement in your revenue cycle, a compliance review before May 15 is worth the time. Your compliance officer can help you assess denial exposure and confirm your documentation standards hold up under CMS scrutiny. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hepatitis Panel Under This Policy
The source policy document did not include specific CPT, HCPCS, or ICD-10 codes in its data. PayerPolicy displays the codes exactly as the payer provides them — we do not add codes that aren't in the source document.
What This Means for Your Team
This is an important gap to close on your own before May 15, 2026. Hepatitis panel testing typically uses a defined set of CPT codes for individual components and panel combinations. The absence of a code list in this policy version does not mean coding is unconstrained — it means you need to verify the applicable codes directly.
Here's where to look:
- The full policy document at the CMS source link: https://app.payerpolicy.org/p/cms/166-v1
- Your MAC's LCD for hepatitis panel testing, if one exists in your region
- The CMS fee schedule for current RVU-based reimbursement values on hepatitis-related panel codes
- The AMA CPT codebook for the current year's hepatitis panel and component code descriptions
If your billing team needs a definitive code list to update charge capture before the effective date of May 15, 2026, contact your MAC directly or reference the full policy document. Do not assume the code set is unchanged from prior years without verifying — CPT code revisions for laboratory panels happen on an annual cycle.
A Note on Panel vs. Component Billing
The distinction between billing a hepatitis panel code versus billing individual component tests matters for reimbursement and claim review. CMS has specific rules about when bundling applies, when individual components can be broken out, and when panel billing is required. This is an area where your billing guidelines need to be current and your team needs to be aligned with the coding standard your MAC enforces.
If you're billing individual components when a panel code should be used — or vice versa — you're creating unbundling exposure or leaving reimbursement on the table. Both outcomes are avoidable with the right code mapping in your charge capture system.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.